Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory study
Background: A new cell-based serum anticholinergic activity (cSAA) assay that measures anticholinergic activity specifically at muscarinic M1 receptors and eliminates many of the drawbacks of the existing assay was developed by our team. Aims: We aimed to study the relationship between changes in wo...
Gespeichert in:
| Veröffentlicht in: | Journal of psychopharmacology (Oxford) 2022-09, Vol.36 (9), p.1070-1076 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1076 |
|---|---|
| container_issue | 9 |
| container_start_page | 1070 |
| container_title | Journal of psychopharmacology (Oxford) |
| container_volume | 36 |
| creator | Chandramouleeshwaran, Susmita Ghazala, Zaid Nobrega, José N Raymond, Roger Gambino, Sara Pollock, Bruce G. Rajji, Tarek K |
| description | Background:
A new cell-based serum anticholinergic activity (cSAA) assay that measures anticholinergic activity specifically at muscarinic M1 receptors and eliminates many of the drawbacks of the existing assay was developed by our team.
Aims:
We aimed to study the relationship between changes in working memory and executive function with changes in cSAA using the new assay in cognitively healthy older adults.
Methods:
Cognitively healthy participants aged 50 years and above, received a single dose of 0.4 mg of intravenous scopolamine. Cognition and cSAA levels were measured before and 30 min after receiving scopolamine. Cognition was measured using the Cambridge Neuropsychological Test Automated Battery.
Results:
Ten participants were recruited, and nine (mean age = 69.8, SD = 9.5, range 59–86 years) completed the study. Following scopolamine, participants experienced an increase in cSAA (cSAA pre = 0.90 ± 0.97 vs cSAA post = 12.0 ± 3.70 pmol/L; t-test (df = (8) = −9.5, p |
| doi_str_mv | 10.1177/02698811221122019 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2718095957</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_02698811221122019</sage_id><sourcerecordid>2718095957</sourcerecordid><originalsourceid>FETCH-LOGICAL-c250t-f1f7006909821ca9ded5c3977cb0114363261305ac186f385c026fe7ba910963</originalsourceid><addsrcrecordid>eNp1kcFO3DAQhi1UBFvgAXqpLPUc6kk2dtwbWgGttBKXvUeOM9n14sRb2wHyKH1bnC5tDxWH8Ujj7_9_aYaQT8CuAYT4ynIuqwogz-diIE_IApYcMpFX5QeymP-zGTgnH0PYMwZ8ycszcl7wJKi4WJBfK7Q2a1TAlgb0Y0_VEI3eOWsG9FujqdLRPJk4URWCSu_Q0mfnH82wpT32zk_UDFS77WASh3aiO1Q27ibqbIueqna0MdAGO-fxt1p1Mc2DdgdnVZ9ivtGbgeLLwTqv4mwY4thOl-S0Uzbg1Vu_IJu7283qe7Z-uP-xullnOi9ZzDroBGNcMlnloJVssS11IYXQDQNYFrzIORSsVBoq3hVVqdNWOhSNksAkLy7Il6PtwbufI4ZY793oh5RY5wIqJktZikTBkdLeheCxqw_e9MpPNbB6vkX93y2S5vOb89j02P5V_Fl-Aq6PQFBb_Bf7vuMrZp6Thg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2718095957</pqid></control><display><type>article</type><title>Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory study</title><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>Chandramouleeshwaran, Susmita ; Ghazala, Zaid ; Nobrega, José N ; Raymond, Roger ; Gambino, Sara ; Pollock, Bruce G. ; Rajji, Tarek K</creator><creatorcontrib>Chandramouleeshwaran, Susmita ; Ghazala, Zaid ; Nobrega, José N ; Raymond, Roger ; Gambino, Sara ; Pollock, Bruce G. ; Rajji, Tarek K</creatorcontrib><description>Background:
A new cell-based serum anticholinergic activity (cSAA) assay that measures anticholinergic activity specifically at muscarinic M1 receptors and eliminates many of the drawbacks of the existing assay was developed by our team.
Aims:
We aimed to study the relationship between changes in working memory and executive function with changes in cSAA using the new assay in cognitively healthy older adults.
Methods:
Cognitively healthy participants aged 50 years and above, received a single dose of 0.4 mg of intravenous scopolamine. Cognition and cSAA levels were measured before and 30 min after receiving scopolamine. Cognition was measured using the Cambridge Neuropsychological Test Automated Battery.
Results:
Ten participants were recruited, and nine (mean age = 69.8, SD = 9.5, range 59–86 years) completed the study. Following scopolamine, participants experienced an increase in cSAA (cSAA pre = 0.90 ± 0.97 vs cSAA post = 12.0 ± 3.70 pmol/L; t-test (df = (8) = −9.5, p < 0.001). In addition, there was an association between change in cSAA and changes in working memory (Spearman’s ρ = 0.68, p = 0.042) and executive function (Spearman’s ρ = 0.72, p = 0.027).
Conclusions:
In our sample of cognitively healthy older adults, the new cSAA assay was able to quantify the scopolamine induced increase in anticholinergic load which correlated significantly with the observed decline in working memory and executive function.</description><identifier>ISSN: 0269-8811</identifier><identifier>EISSN: 1461-7285</identifier><identifier>DOI: 10.1177/02698811221122019</identifier><identifier>PMID: 36112867</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Acetylcholine receptors (muscarinic) ; Aged ; Aged, 80 and over ; Anticholinergics ; Cholinergic Antagonists - adverse effects ; Cognition ; Executive function ; Humans ; Intravenous administration ; Memory ; Memory, Short-Term ; Middle Aged ; Neuropsychological Tests ; Older people ; Receptor, Muscarinic M1 ; Scopolamine ; Scopolamine - pharmacology ; Short term memory</subject><ispartof>Journal of psychopharmacology (Oxford), 2022-09, Vol.36 (9), p.1070-1076</ispartof><rights>The Author(s) 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c250t-f1f7006909821ca9ded5c3977cb0114363261305ac186f385c026fe7ba910963</cites><orcidid>0000-0003-2295-852X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/02698811221122019$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/02698811221122019$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36112867$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chandramouleeshwaran, Susmita</creatorcontrib><creatorcontrib>Ghazala, Zaid</creatorcontrib><creatorcontrib>Nobrega, José N</creatorcontrib><creatorcontrib>Raymond, Roger</creatorcontrib><creatorcontrib>Gambino, Sara</creatorcontrib><creatorcontrib>Pollock, Bruce G.</creatorcontrib><creatorcontrib>Rajji, Tarek K</creatorcontrib><title>Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory study</title><title>Journal of psychopharmacology (Oxford)</title><addtitle>J Psychopharmacol</addtitle><description>Background:
A new cell-based serum anticholinergic activity (cSAA) assay that measures anticholinergic activity specifically at muscarinic M1 receptors and eliminates many of the drawbacks of the existing assay was developed by our team.
Aims:
We aimed to study the relationship between changes in working memory and executive function with changes in cSAA using the new assay in cognitively healthy older adults.
Methods:
Cognitively healthy participants aged 50 years and above, received a single dose of 0.4 mg of intravenous scopolamine. Cognition and cSAA levels were measured before and 30 min after receiving scopolamine. Cognition was measured using the Cambridge Neuropsychological Test Automated Battery.
Results:
Ten participants were recruited, and nine (mean age = 69.8, SD = 9.5, range 59–86 years) completed the study. Following scopolamine, participants experienced an increase in cSAA (cSAA pre = 0.90 ± 0.97 vs cSAA post = 12.0 ± 3.70 pmol/L; t-test (df = (8) = −9.5, p < 0.001). In addition, there was an association between change in cSAA and changes in working memory (Spearman’s ρ = 0.68, p = 0.042) and executive function (Spearman’s ρ = 0.72, p = 0.027).
Conclusions:
In our sample of cognitively healthy older adults, the new cSAA assay was able to quantify the scopolamine induced increase in anticholinergic load which correlated significantly with the observed decline in working memory and executive function.</description><subject>Acetylcholine receptors (muscarinic)</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anticholinergics</subject><subject>Cholinergic Antagonists - adverse effects</subject><subject>Cognition</subject><subject>Executive function</subject><subject>Humans</subject><subject>Intravenous administration</subject><subject>Memory</subject><subject>Memory, Short-Term</subject><subject>Middle Aged</subject><subject>Neuropsychological Tests</subject><subject>Older people</subject><subject>Receptor, Muscarinic M1</subject><subject>Scopolamine</subject><subject>Scopolamine - pharmacology</subject><subject>Short term memory</subject><issn>0269-8811</issn><issn>1461-7285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFO3DAQhi1UBFvgAXqpLPUc6kk2dtwbWgGttBKXvUeOM9n14sRb2wHyKH1bnC5tDxWH8Ujj7_9_aYaQT8CuAYT4ynIuqwogz-diIE_IApYcMpFX5QeymP-zGTgnH0PYMwZ8ycszcl7wJKi4WJBfK7Q2a1TAlgb0Y0_VEI3eOWsG9FujqdLRPJk4URWCSu_Q0mfnH82wpT32zk_UDFS77WASh3aiO1Q27ibqbIueqna0MdAGO-fxt1p1Mc2DdgdnVZ9ivtGbgeLLwTqv4mwY4thOl-S0Uzbg1Vu_IJu7283qe7Z-uP-xullnOi9ZzDroBGNcMlnloJVssS11IYXQDQNYFrzIORSsVBoq3hVVqdNWOhSNksAkLy7Il6PtwbufI4ZY793oh5RY5wIqJktZikTBkdLeheCxqw_e9MpPNbB6vkX93y2S5vOb89j02P5V_Fl-Aq6PQFBb_Bf7vuMrZp6Thg</recordid><startdate>202209</startdate><enddate>202209</enddate><creator>Chandramouleeshwaran, Susmita</creator><creator>Ghazala, Zaid</creator><creator>Nobrega, José N</creator><creator>Raymond, Roger</creator><creator>Gambino, Sara</creator><creator>Pollock, Bruce G.</creator><creator>Rajji, Tarek K</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><orcidid>https://orcid.org/0000-0003-2295-852X</orcidid></search><sort><creationdate>202209</creationdate><title>Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory study</title><author>Chandramouleeshwaran, Susmita ; Ghazala, Zaid ; Nobrega, José N ; Raymond, Roger ; Gambino, Sara ; Pollock, Bruce G. ; Rajji, Tarek K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c250t-f1f7006909821ca9ded5c3977cb0114363261305ac186f385c026fe7ba910963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Acetylcholine receptors (muscarinic)</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anticholinergics</topic><topic>Cholinergic Antagonists - adverse effects</topic><topic>Cognition</topic><topic>Executive function</topic><topic>Humans</topic><topic>Intravenous administration</topic><topic>Memory</topic><topic>Memory, Short-Term</topic><topic>Middle Aged</topic><topic>Neuropsychological Tests</topic><topic>Older people</topic><topic>Receptor, Muscarinic M1</topic><topic>Scopolamine</topic><topic>Scopolamine - pharmacology</topic><topic>Short term memory</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chandramouleeshwaran, Susmita</creatorcontrib><creatorcontrib>Ghazala, Zaid</creatorcontrib><creatorcontrib>Nobrega, José N</creatorcontrib><creatorcontrib>Raymond, Roger</creatorcontrib><creatorcontrib>Gambino, Sara</creatorcontrib><creatorcontrib>Pollock, Bruce G.</creatorcontrib><creatorcontrib>Rajji, Tarek K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Journal of psychopharmacology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chandramouleeshwaran, Susmita</au><au>Ghazala, Zaid</au><au>Nobrega, José N</au><au>Raymond, Roger</au><au>Gambino, Sara</au><au>Pollock, Bruce G.</au><au>Rajji, Tarek K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory study</atitle><jtitle>Journal of psychopharmacology (Oxford)</jtitle><addtitle>J Psychopharmacol</addtitle><date>2022-09</date><risdate>2022</risdate><volume>36</volume><issue>9</issue><spage>1070</spage><epage>1076</epage><pages>1070-1076</pages><issn>0269-8811</issn><eissn>1461-7285</eissn><abstract>Background:
A new cell-based serum anticholinergic activity (cSAA) assay that measures anticholinergic activity specifically at muscarinic M1 receptors and eliminates many of the drawbacks of the existing assay was developed by our team.
Aims:
We aimed to study the relationship between changes in working memory and executive function with changes in cSAA using the new assay in cognitively healthy older adults.
Methods:
Cognitively healthy participants aged 50 years and above, received a single dose of 0.4 mg of intravenous scopolamine. Cognition and cSAA levels were measured before and 30 min after receiving scopolamine. Cognition was measured using the Cambridge Neuropsychological Test Automated Battery.
Results:
Ten participants were recruited, and nine (mean age = 69.8, SD = 9.5, range 59–86 years) completed the study. Following scopolamine, participants experienced an increase in cSAA (cSAA pre = 0.90 ± 0.97 vs cSAA post = 12.0 ± 3.70 pmol/L; t-test (df = (8) = −9.5, p < 0.001). In addition, there was an association between change in cSAA and changes in working memory (Spearman’s ρ = 0.68, p = 0.042) and executive function (Spearman’s ρ = 0.72, p = 0.027).
Conclusions:
In our sample of cognitively healthy older adults, the new cSAA assay was able to quantify the scopolamine induced increase in anticholinergic load which correlated significantly with the observed decline in working memory and executive function.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>36112867</pmid><doi>10.1177/02698811221122019</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-2295-852X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-8811 |
| ispartof | Journal of psychopharmacology (Oxford), 2022-09, Vol.36 (9), p.1070-1076 |
| issn | 0269-8811 1461-7285 |
| language | eng |
| recordid | cdi_proquest_journals_2718095957 |
| source | SAGE Complete A-Z List; MEDLINE |
| subjects | Acetylcholine receptors (muscarinic) Aged Aged, 80 and over Anticholinergics Cholinergic Antagonists - adverse effects Cognition Executive function Humans Intravenous administration Memory Memory, Short-Term Middle Aged Neuropsychological Tests Older people Receptor, Muscarinic M1 Scopolamine Scopolamine - pharmacology Short term memory |
| title | Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T04%3A49%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cell-based%20serum%20anticholinergic%20activity%20assay%20and%20working%20memory%20in%20cognitively%20healthy%20older%20adults%20before%20and%20after%20scopolamine:%20An%20exploratory%20study&rft.jtitle=Journal%20of%20psychopharmacology%20(Oxford)&rft.au=Chandramouleeshwaran,%20Susmita&rft.date=2022-09&rft.volume=36&rft.issue=9&rft.spage=1070&rft.epage=1076&rft.pages=1070-1076&rft.issn=0269-8811&rft.eissn=1461-7285&rft_id=info:doi/10.1177/02698811221122019&rft_dat=%3Cproquest_cross%3E2718095957%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2718095957&rft_id=info:pmid/36112867&rft_sage_id=10.1177_02698811221122019&rfr_iscdi=true |